AZmed, a pioneering MedTech startup based in Paris, France, specializing in AI-powered radiology software, has successfully raised €15 million in funding. The investment round garnered support from prominent investors, including Maison Worms, Techstars, and Teampact Ventures.

The primary objective behind this funding is to bolster AZmed’s expansion efforts within the field of medical imaging powered by artificial intelligence. With a focus on accelerating radiologists’ workflows, the company aims to solidify its position as a leader in Europe while extending its footprint globally, particularly in regions such as the United States, the Middle East, Africa, and Asia.

Under the leadership of CEO Julien Vidal, AZmed has been instrumental in commercializing AI-powered radiology software tailored to streamline trauma and chest X-ray diagnostics. By leveraging artificial intelligence, these solutions significantly enhance efficiency, allowing medical professionals to allocate more time and resources to critical examinations.

Currently, AZmed’s solutions are already operational in over 1000 healthcare institutions worldwide. Remarkably, they are utilized by more than 9000 physicians daily across 40 countries and 5 continents, illustrating the widespread adoption and impact of their technology.

Julien Vidal, expressing his enthusiasm about the recent funding, emphasized the pivotal role of AI in revolutionizing the medical imaging industry. He stated, “We are thrilled to have obtained this funding to advance AZmed to the forefront of the medical imaging industry. As the number of physicians has remained constant while the volume of medical images has increased, it is beyond dispute that each medical image must be correlated with a diagnosis of AI. Hence, AZmed is determined to pioneer the development of AI solutions in radiology to efficiently support the growing flow of images and improve the patient care pathway.”

The funding secured by AZmed comes at a time when the global market for AI diagnostic imaging is experiencing exponential growth. According to analysis by GlobalData, the market is projected to exceed $1.2 billion by 2027, showcasing the immense potential and demand for AI-driven solutions in the healthcare sector.

Moreover, AZmed’s innovative approach aligns with the broader trend of increased investment in AI-enabled medical imaging and diagnostics. In 2023 alone, numerous companies, including US-based Clarix Imaging, secured significant capital to advance the utilization of AI in imaging technologies.

With this latest funding injection, AZmed is well-positioned to further innovate and drive transformative change in the realm of medical imaging, ultimately enhancing patient care and outcomes on a global scale.